Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study-Reference-Cited by-同舟云学术

Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study

Published:2018-08-31 Issue:11 Volume:93 Page:1311-1317
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Flinn Ian W.¹²,Patel Manish¹³,Oki Yasuhiro⁴,Horwitz Steven⁵,Foss Francine F.⁶,Allen Kerstin⁷,Douglas Mark⁷,Stern Howard⁷,Sweeney Jennifer⁷,Kharidia Jahnavi⁷,Kelly Patrick⁷,Kelly Virginia M.⁷,Kahl Brad⁸

Affiliation:

1. Sarah Cannon Research Institute; Nashville Tennessee

2. Tennessee Oncology; Nashville Tennessee

3. Florida Cancer Specialists; Sarasota Florida

4. MD Anderson Cancer Center; Houston Texas

5. Memorial Sloan Kettering Cancer Center; New York New York

6. Yale University Cancer Center; New Haven Connecticut

7. Infinity Pharmaceuticals, Inc.; Cambridge Massachusetts

8. Washington University; St. Louis Missouri

Funder

Infinity Pharmaceuticals

Vera Bradley Foundation for Breast Cancer

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.25228/fullpdf

Reference41 articles.

1. Cancer statistics, 2014;Siegel;CA Cancer J Clin,2014

2. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

3. Follicular lymphoma: current management and future directions;Bello;Cancer Control,2012

4. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation;Clayton;J Exp Med.,2002

5. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice;Okkenhaug;Science.,2002

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post-marketing safety concern of PI3K inhibitors in the cancer therapies: an 8-year disproportionality analysis from the FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-07-31

2. The PI3K signaling pathway; from normal lymphopoiesis to lymphoid malignancies;Expert Review of Anticancer Therapy;2024-05-08

3. SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas;Clinical Lymphoma Myeloma and Leukemia;2024-02

4. Research Progress in the Treatment of Non Hodgkin’s Lymphoma;Journal of Clinical Personalized Medicine;2024

5. New anticancer therapeutics impact fungal pathobiology, infection dynamics, and outcome;PLOS Pathogens;2023-12-21